New immune therapy trial aims to tame Tough-to-Treat lymphoma
NCT ID NCT07365306
Summary
This study is testing a new combination of drugs for adults with an aggressive type of lymphoma (DLBCL) that has returned or not responded to prior treatment. The goal is to see if this therapy can effectively shrink the cancer and prepare patients for a stem cell transplant, a potentially curative procedure. The treatment combines a new immune-boosting drug (epcoritamab) with standard chemotherapy and an antibody (rituximab).
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Atlanta Cancer Center
Newnan, Georgia, 30265, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
City of Hope at Chicago
Zion, Illinois, 60099, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.